Aclarion, Inc. ACON 深 沪
已收盘 12-19 16:00:00 美东时间
6.20
-0.140
-2.21%
华盛通- 最 高8.09
- 今 开6.29
- 成交量 18.36万股
- 最 低 5.55
- 昨 收 6.34
- 总市值 4452.03万
- 52周最高 15.08
- 市盈率 静 --
- 换手率 2.56%
- 52周最低 0.0281
- 委 比 99.38%
- 总股本 718.07万
- 历史最高 15.08
- 量 比 1.79
- 振 幅 40.06%
- 历史最低 0.0281
- 每 手 1
- 风险率 2.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多洲际船务附属拟租赁三艘散货船
洲际船务（02409）发布公告，于2025年10月16日（联交所交易时段后），（1）各租船人（为本公司三间间接全资附属公司，SEACON ATLANTA ...
10-17 08:28
连成科技集团(08635)股份简称将于6月25日起变更为“大象控股集团”
连成科技集团(08635)公布，股份于联交所买卖的英文股份简称将由“NOVACON TECH”变更为“ELEPHANT HLDGS”，而中文股份简称将由“连成科...
06-20 20:09
Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site
UHealth and the University of Miami Miller School of Medicine join the CLARITY trial to evaluate Nociscan's ability to improve spine surgery outcomes for chronic low back pain using MR Spectroscopy and AI.
06-10 10:00
康宁杰瑞制药股价大涨，此前遭恒生综合指数剔除
2月27日收盘，康宁杰瑞制药-B（09966）报收于6.08港元，上涨22.33%，换手率3.63%，成交量3496.52万股，成交额2.05亿港元。公司股价已...
02-28 09:46
Aclarion Added To PRISM Emerging Medical Devices Index, Co's Technology Addresses Chronic Low Back Pain; Aclarion Secured Its First Commercial Agreement With Michigan's Sheridan Community Hospital
Company's industry-first technology addresses chronic low back painAclarion secured its first commercial agreement with Michigan's Sheridan Community Hospital PRISM Emerging Medical Devices Index features companies
2024-09-06 23:29
Micron To $140? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham cut the price target for Micron Technology Inc (NASDAQ:MU) from $150 to $140. Needham analyst Quinn Bo...
2024-08-26 20:32
Ascendiant Capital Maintains Buy on Aclarion, Lowers Price Target to $1.5
Ascendiant Capital analyst Lucas Ward maintains Aclarion (NASDAQ:ACON) with a Buy and lowers the price target from $1.6 to $1.5.
2024-08-26 17:50
Aclarion Launches The Clinical Utility And Economic Trial To Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans
Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data Multiple Physicians and Sites Will Enroll in CLUE in the Coming Months Adding Practical Real-world Data to Aclarion's Expanding Body of Clinical Evide...
2024-08-21 20:02
